AU2006319244B2 - Serotonin transporter (SERT) inhibitors - Google Patents

Serotonin transporter (SERT) inhibitors Download PDF

Info

Publication number
AU2006319244B2
AU2006319244B2 AU2006319244A AU2006319244A AU2006319244B2 AU 2006319244 B2 AU2006319244 B2 AU 2006319244B2 AU 2006319244 A AU2006319244 A AU 2006319244A AU 2006319244 A AU2006319244 A AU 2006319244A AU 2006319244 B2 AU2006319244 B2 AU 2006319244B2
Authority
AU
Australia
Prior art keywords
phenyl
pyrrolidine
benzyloxymethyl
trifluoromethyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006319244A
Other languages
English (en)
Other versions
AU2006319244A1 (en
Inventor
Christophe Grundschober
Torsten Hoffmann
Andreas Koblet
Patrick Schnider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2006319244A1 publication Critical patent/AU2006319244A1/en
Application granted granted Critical
Publication of AU2006319244B2 publication Critical patent/AU2006319244B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006319244A 2005-12-01 2006-11-22 Serotonin transporter (SERT) inhibitors Ceased AU2006319244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05111565.7 2005-12-01
EP05111565 2005-12-01
PCT/EP2006/068740 WO2007063009A1 (en) 2005-12-01 2006-11-22 Serotonin transporter (sert) inhibitors

Publications (2)

Publication Number Publication Date
AU2006319244A1 AU2006319244A1 (en) 2007-06-07
AU2006319244B2 true AU2006319244B2 (en) 2011-07-07

Family

ID=37686112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006319244A Ceased AU2006319244B2 (en) 2005-12-01 2006-11-22 Serotonin transporter (SERT) inhibitors

Country Status (13)

Country Link
US (1) US20070129419A1 (https=)
EP (1) EP1957450B1 (https=)
JP (1) JP5020967B2 (https=)
KR (1) KR101091376B1 (https=)
CN (1) CN101316816B (https=)
AT (1) ATE434605T1 (https=)
AU (1) AU2006319244B2 (https=)
BR (1) BRPI0619154A2 (https=)
CA (1) CA2631221C (https=)
DE (1) DE602006007483D1 (https=)
ES (1) ES2326285T3 (https=)
IL (1) IL191468A (https=)
WO (1) WO2007063009A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8471040B2 (en) * 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US20160009694A1 (en) * 2013-03-15 2016-01-14 Portola Pharmaceuticals, Inc. Cyclohexanediamine compounds and methods for their preparation
CA2949160C (en) 2014-05-15 2023-03-21 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
PT3344248T (pt) 2015-09-02 2022-06-29 Trevena Inc Compostos moduladores do recetor opioide delta contendo aza-heterocíclicos de 6 membros, composições compreendendo os mesmos e seus usos
US11225487B2 (en) 2017-02-17 2022-01-18 Trevena, Inc. 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same
BR112019016827A2 (pt) 2017-02-17 2020-04-07 Trevena Inc compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
BR112022016941A2 (pt) * 2020-02-25 2022-10-25 Tes Pharma S R L Compostos heterocíclicos para a modulação de nr2f6

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032464A2 (en) * 2003-09-30 2005-04-14 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
ATE374183T1 (de) * 2001-11-13 2007-10-15 Schering Corp Nk1-antagonisten
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032464A2 (en) * 2003-09-30 2005-04-14 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists

Also Published As

Publication number Publication date
CN101316816A (zh) 2008-12-03
JP2009517435A (ja) 2009-04-30
WO2007063009A1 (en) 2007-06-07
JP5020967B2 (ja) 2012-09-05
EP1957450A1 (en) 2008-08-20
CA2631221C (en) 2014-06-03
KR101091376B1 (ko) 2011-12-07
CN101316816B (zh) 2011-07-27
ATE434605T1 (de) 2009-07-15
EP1957450B1 (en) 2009-06-24
IL191468A (en) 2012-02-29
DE602006007483D1 (https=) 2009-08-06
US20070129419A1 (en) 2007-06-07
AU2006319244A1 (en) 2007-06-07
CA2631221A1 (en) 2007-06-07
BRPI0619154A2 (pt) 2011-09-20
ES2326285T3 (es) 2009-10-06
KR20080064200A (ko) 2008-07-08

Similar Documents

Publication Publication Date Title
CA2682506C (en) Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
AU2004247487B2 (en) N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
IL191468A (en) Serotonin transporter (sert) inhibitors, process for their preparation, medicaments containing them and use thereof in the preparation of medicaments for the treatment of anxiety and depression
IL174936A (en) Derivatives of n-[phenyl(alkylpiperidine-2- yl) methyl] benzamide, medicaments and pharmaceutical compositions comprising them and their use in the preparation of medicaments
US7528136B2 (en) Prolinamide derivatives as NK3 antagonists
IL174934A (en) Derivatives of n - [phenyl(2-pyrrolidinyl) methyl] benzamide and n - [phenyl (2 - azepanyl) methyl] benzamide, medicament thereof, pharmaceutical composition thereof and use thereof in the preparation of a medicament
EP2364295B1 (en) 3-(benzylamino)-pyrrolidine derivatives and their use as nk-3 receptor antagonists
CA2648065C (en) Piperidine derivatives useful as serotonin transporter inhibitors and neurokinin-1 receptor antagonists
US7501422B2 (en) Prolinamide-tetrazole derivatives as NK3 receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired